Literature DB >> 19609245

Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.

Ilka Knippertz1, Andrea Hesse, Tanja Schunder, Eckhart Kämpgen, Malcolm K Brenner, Gerold Schuler, Alexander Steinkasserer, Dirk M Nettelbeck.   

Abstract

Dendritic cells (DCs) are professional antigen presenting cells and have key functions in the initiation of immune responses. Hence, antigen-loaded DCs have become important tools for active-specific immunotherapy. In addition to defining strategies for antigen loading, effective T-cell activation by DCs will depend on vaccination protocols that facilitate DC migration to secondary lymphoid tissues and expression of costimulatory molecules and cytokines. Adenoviral gene transfer has been successfully implemented for genetic antigen loading of DCs. In this study, we exploit an adenoviral vector encoding human CD40 ligand (CD40L), Ad5hCD40L, to establish DCs that feature both migration potential and prolonged secretion of the key T-helper 1 cytokine interleukin-12p70 (IL-12p70). Transduction of human monocyte-derived DCs with Ad5hCD40L resulted in efficient CD40L expression, which was detected only intracellularly, and in secretion of IL-12p70. Addition of recombinant interferon (IFN)-gamma shortly after DC transduction substantially increased IL-12p70 secretion. Maturation of DCs was achieved with a standard cytokine maturation cocktail (MC) containing prostaglandin E2 which, however, abolished IL-12p70 secretion by Ad5hCD40L-transduced cells in the absence of IFN-gamma. Only DCs treated with Ad5hCD40L, MC, and IFN-gamma migrated efficiently towards CCL19 and continued to secrete IL-12p70. Finally, DCs transduced with both Ad5hCD40L and an adenoviral vector encoding the melanoma antigen MelanA/MART-1 and treated with MC and IFN-gamma efficiently primed naive autologous CD8+ T cells into antigen-specific cytotoxic T lymphocyte. This strategy to generate DCs that exert both migration capacity and prolonged IL-12p70 secretion after intracellular CD40L expression and IFN-gamma treatment has the potential to further improve current DC vaccination protocols.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609245     DOI: 10.1097/CJI.0b013e3181a28422

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  13 in total

Review 1.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 2.  Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Transfus Med Hemother       Date:  2020-10-28       Impact factor: 3.747

Review 3.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

4.  Multiple interferon regulatory factor and NF-κB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells.

Authors:  Marcello F Stein; Stefan Lang; Thomas H Winkler; Andrea Deinzer; Sebastian Erber; Dirk M Nettelbeck; Elisabeth Naschberger; Ramona Jochmann; Michael Stürzl; Robert K Slany; Thomas Werner; Alexander Steinkasserer; Ilka Knippertz
Journal:  Mol Cell Biol       Date:  2013-01-22       Impact factor: 4.272

5.  Designing the optimal vaccine: the importance of cytokines and dendritic cells.

Authors:  Penelope A Morel; Michael S Turner
Journal:  Open Vaccine J       Date:  2010

Review 6.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

Review 7.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 8.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.

Authors:  Nicola Hardwick; Jonathan A Ledermann; Egla Aitkens; Benny Chain
Journal:  Cancer Immunol Immunother       Date:  2012-04-05       Impact factor: 6.968

Review 10.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.